Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724836 | 0.72 | SLC7A5 (0.39) | TSHRKDM4EMEN1ALDH1A1RAB9A | |
| SCHEMBL7707572 | 0.71 | TSHR (0.39) | TSHRADH1BADH1CADH1AS1PR1 | |
| SCHEMBL973483 | 0.71 | HSD11B1 (0.37) | TSHRADH1CADH1AFDPSKDM4E | |
| SCHEMBL18827887 | 0.69 | TSHR (0.35) | TSHR | |
| SCHEMBL10579327 | 0.69 | ALOX5 (0.33) | TSHRFDPSKDM4EMEN1ALDH1A1 | |
| SCHEMBL11135152 | 0.67 | HSD11B1 (0.35) | TSHRADH1CADH1AFDPSKDM4E | |
| SCHEMBL6932731 | 0.67 | HSD11B1 (0.39) | TSHRADH1CADH1AFDPSKDM4E | |
| SCHEMBL6377049 | 0.67 | HTT (0.30) | — | |
| SCHEMBL9618364 | 0.67 | SMN1; SMN2 (0.43) | TSHRS1PR1MEN1ALDH1A1RAB9A | |
| SCHEMBL28490982 | 0.66 | LMNA (0.40) | ADH1CADH1AFDPSKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473803-B2 | Process for production of optically active 2-halogeno-carboxylic acids | KANEKA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20050176999-A1 | Process for production of optically active 2-halogeno-carboxylic acids | KANEKA CORPORATION (JP) | 2005-08-11 | — | — | US | disclosed |
| EP-1481960-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-HALOGENO- CARBOXYLIC ACIDS | KANEKA CORPORATION (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176999-A1 | Process for production of optically active 2-halogeno-carboxylic acids | HAO2, HCAR2, HAAO | TSHR 1455/4885ADH1B 590/4885ADH1C 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.